{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-013048","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.881826+00:00","generated_at":"2026-05-20T04:27:01.015054+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones","bullets":["Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.","Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.","Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-013048","json":"https://secwatch.observer/filing/0001641172-25-013048.json","markdown":"https://secwatch.observer/filing/0001641172-25-013048.md","text":"https://secwatch.observer/filing/0001641172-25-013048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000164117225013048/0001641172-25-013048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000164117225013048/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:27:01.015054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}